NLRP3 and psoriasis: In contrast, methotrexate, a folate antagonist used for the treatment of severe inflammatory conditions, including psoriasis, did not reduce caspase-1 activity in psoriasis patients, suggesting that TNF-α inhibition is superior in reducing NLRP3-dependent inflammation during psoriasis.